Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
Open Access
- 13 February 2021
- journal article
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 7 (1), 010-015
- https://doi.org/10.17352/2581-5407.000037
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Outcome disparities in multiple myeloma: a SEER‐based comparative analysis of ethnic subgroupsBritish Journal of Haematology, 2012
- Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patientsAnnals of Oncology, 2011
- Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisoneBlood, 2010
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyLeukemia, 2010
- The role of complete response in multiple myelomaBlood, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myelomaHaematologica, 2007
- Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trialsBlood, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003